查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
再生医学市场：2023年至2028年预测
市场调查报告书
商品编码
1410262

再生医学市场：2023年至2028年预测

Regenerative Medicine Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 139 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球再生医学市场预计将从2021年的251.49亿美元增加至2028年的1,223.81亿美元，预测期内年复合成长率为25.36%。

由于技术、研究和临床试验的进步，再生医学在医学领域取得了长足的进步。再生医学包括多种技术，包括干细胞疗法，它具有分化为体内不同类型细胞的独特能力。干细胞疗法涉及将干细胞移植到受损组织中，在那里它们分化成修復和再生所需的特定细胞类型。基因治疗涉及将遗传物质引入细胞以纠正或替换有缺陷的基因。组织工程是利用细胞、支架和其他材料製造人造组织。

再生医学提供了个人化医疗的潜力，即根据患者独特的遗传和医学特征为其量身定制治疗方法。这可以实现更有效、更有针对性的治疗，同时减少副作用。

再生医学有着广泛的应用。

此外，再生医学广泛应用于各医学领域。目前正在研究治疗阿兹海默症、帕金森氏症、多发性硬化症等神经系统疾病以及心臟病（这是全球主要死亡原因）。例如，干细胞疗法在修復受损心臟组织和改善心臟衰竭患者的心臟功能方面已显示出希望。例如，CRISPR/Cas9是一种基因编辑技术，透过指导细胞的命运来实现再生医学2.0。 CRISPR/Cas9系统利用Cas9核酸酶和可程式设计单嚮导RNA（sgRNA）的协同作用，广泛用于基因组编辑。研究人员正在使用 CRISPR/Cas9 透过体外编辑来保护移植细胞免受患者免疫系统的影响。使用 CRISPR/Cas9 的基因疗法正在用于治疗遗传性酪胺酸血症，这是一种罕见的代谢性疾病。来自马萨诸塞大学、麻省理工学院 (MIT) 和奥勒冈健康与科学大学 (OHSU) 的研究人员最近成功开发了一种基于 CRISPR-Cas9 的基因疗法。

此外，再生医学领域正在迅速发展，许多不同的细分领域和子领域都出现了重大进步和创新。再生医学发展的驱动力包括慢性病的日益普及、人口老化以及当前组织损伤和退化性疾病治疗方法的限制。再生医学有潜力为这些病症提供更有效、更持久的解决方案。用于开发和製造再生医学的技术包括生物技术、细胞培养、基因编辑和奈米技术。这些技术可以精确操纵细胞和遗传物质，以创建客製化的再生疗法。

医疗保健领域的科学技术进步

医疗保健领域对再生医学的需求不断增长主要是由于科学的进步。干细胞研究的最新进展导致了针对多种疾病的新治疗方法的开发，包括心臟病、帕金森氏症和糖尿病。这正在推动再生医学的发展。例如，2020年，诺华公司的基因治疗药物Zolgensma获得欧洲药品管理局的核准，用于治疗脊髓性肌肉萎缩症。 Zolgensma 是世界上最昂贵的药物，每剂售价 210 万美元（约 2 亿日圆）。

此外，组织工程利用生物材料、细胞和其他成分来製造人造组织和器官。组织工程技术的进步，例如 3D 列印和生物材料的开发，正在创造功能性组织和器官，例如心臟组织、肝臟组织和皮肤。例如，专注于开发神经系统疾病细胞治疗方法的 BlueRock Therapeutics 宣布其帕金森氏症计画于 2020 年获得了积极的临床前资料。这些资料显示 BlueRock 的细胞疗法可改善帕金森氏症动物模型的运动功能。

此外，在分子和细胞层面上对疾病机制的研究导致了新治疗标靶的确定和更有针对性的治疗方法的开发。这种理解也导致了可用于诊断疾病和监测治疗效果的生物标记的鑑定。 CRISPR-Cas9等基因编辑技术使研究人员能够精确编辑和修改基因，为新治疗方法的开发提供了巨大的潜力。例如，基因编辑可用于纠正导致遗传性疾病的基因突变或增强免疫系统来对抗癌症。

此外，政府对再生医学研发的支持和资助也是再生医学市场的主要驱动因素。世界各国政府正在投资再生医学研究并资助临床试验，以协助推动该领域并将新治疗方法推向市场。例如，专门从事细胞治疗方法开发的ana Biotechnology公司在2020年筹集了7亿美元的资金。这笔资金将用于推进 Sana 的细胞治疗方法系列，包括癌症和遗传疾病的治疗方法。

干细胞治疗技术的全球再生医学市场

干细胞疗法是一个快速发展的再生医学领域，利用干细胞来修復或取代受损的组织和器官。干细胞是未分化的细胞，可以分化成体内的各种细胞，使其成为治疗各种疾病和病症的理想选择。

糖尿病、心臟病和癌症等慢性疾病的盛行率在全球范围内不断增加，增加了对创新和有效治疗方法的需求。干细胞疗法透过修復或替换受损的组织和器官，为治疗这些疾病提供了一个有前景的解决方案。世界卫生组织 (WHO) 估计，2020 年全球将新增 1,930 万癌症病例，并有 1,000 万名癌症相关死亡病例。这凸显了癌症对全球造成的巨大负担以及对干细胞疗法等有效治疗方法的需求。此外，干细胞治疗领域近年来获得了大量投资和资金，推动了新治疗方法的研究和开发。美国国立卫生研究院 (NIH) 是政府最大的干细胞研究资助者之一。 2019年，NIH在干细胞研究上投资超过15亿美元，显示了政府对这项技术的支持程度。

此外，诱导性多功能干细胞(iPSC) 和 CRISPR 基因编辑等干细胞技术的进步使得创建和操作干细胞变得更加容易，从而实现更有效率、更有效的治疗方法。

重症疾病对市场的影响

此外，癌症、失智症、帕金森氏症和阿兹海默症严重的流行也对干细胞治疗领域产生重大影响。干细胞疗法可用于治疗多种类型的癌症，包括白血病和淋巴瘤等血癌，以及乳癌和肺癌等固体癌。癌症患者的数量正在推动干细胞疗法作为潜在治疗选择的需求。例如，对于血癌，干细胞移植是一种既定的治疗方法，可以用健康的干细胞取代生病或受损的骨髓。随着癌症患者数量的增加，对干细胞移植的需求也可能增加。除了用作治疗选择之外，干细胞疗法也是开发新癌症治疗方法的一个有前景的研究领域。例如，可以对干细胞进行基因改造以生产抗癌药物或特异性针对癌细胞。这种方法在临床前研究中显示出前景，并且也在临床试验中进行研究。因此，癌症患者的数量将透过推动新治疗方法的需求、增加研发投资以及影响资金和资源的可用性来影响干细胞治疗领域的市场区隔，这是有可能的。

在北美，美国预计将占据最大的市场占有率

再生医学可以产生健康的细胞和组织，并可以取代因某些重大疾病或损伤而受损的细胞。由于其高再生潜力，这些药物也进入了基因治疗和组织工程领域。

鑑于心血管和皮肤疾病的盛行率不断上升以及意外伤害的急剧增加，美国再生医学的前景乐观。美国疾病管制与预防中心的资料显示，美国有69.7万人死于中暑，比2019年增加了5.7%。此外，根据同一资讯来源，死于冠心病的美国人数为 382,​​820 人。

皮肤病也是影响美国人的主要疾病之一。据美国皮肤病学会称，异位性皮肤炎、干癣、酒糟和皮肤癌等皮肤病每年影响 5000 万美国人。

例如，2022 年 4 月，Enzyvant 宣布计划在北卡罗来纳州建立製造工厂。这座占地 25,972 平方英尺的设施将专注于开发针对先天性无胸腺等罕见疾病的再生医学。除了该设施的建立外，食品药物管理局(FDA) 于 2017 年 11 月宣布的综合再生医学政策为美国此类药物的开发建立了框架，从而扩大了预测期内的整体市场。生长。

市场主要发展

  • 2022年9月，Alkem Laboratories与Stempeutics合作推出印度首个细胞疗法StemOne，用于治疗膝骨关节炎。该产品已获得印度药品监督（DCGI）的监管核准，标誌着同种异体细胞治疗产品在印度首次商业性用于治疗膝骨关节炎。 StemOne 由来自培养的混合骨髓的同种异体间质基质细胞组成。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 研究设计
  • 调查资料
  • 检验

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章全球再生医学市场：依技术分类

  • 介绍
  • 干细胞疗法
  • 基因治疗
  • 人体组织工程
  • 其他的

第六章全球再生医学市场：依应用分类

  • 介绍
  • 心血管
  • 肿瘤学
  • 皮肤科
  • 整形外科和肌肉骨骼系统
  • 创伤治疗
  • 眼科
  • 其他的

第七章全球再生医学市场：依最终使用者分类

  • 介绍
  • 医院
  • 诊所
  • 其他的

第八章全球再生医学市场：按地区

  • 介绍
  • 北美洲
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作

第十章 公司简介

  • Novartis
  • Biogen
  • GlaxoSmithKline（GSK）
  • Baxter International, Inc.
  • Boehringer Ingelheim
  • Amgen Inc.
  • Integra Lifesciences Corp.
简介目录
Product Code: KSI061611493

The worldwide regenerative medicine market is anticipated to achieve a compound annual growth rate of 25.36% throughout the forecast period, reaching a value of US$122.381 billion by 2028, up from US$25.149 billion in 2021.

Regenerative medicines are making significant progress in the field of medicine due to advances in technology, research, and clinical trials. There are several technologies for regenerative medicines, including stem cell therapies, that have the unique ability to differentiate into many different types of cells in the body. Stem cell therapies involve the transplantation of stem cells into damaged tissues, where they can differentiate into the specific cell types needed for repair and regeneration. Gene therapies involve the delivery of genetic material to cells to correct or replace defective genes. Tissue engineering involves the creation of artificial tissues using cells, scaffolds, and other materials.

Regenerative medicines offer the potential for personalized medicine, where treatments are tailored to individual patients based on their unique genetic and medical profiles. This can lead to more effective and targeted treatments, with fewer side effects.

Regenerative Medicine used in a broad range of Applications.

Further, regenerative medicine has a broad range of applications across various medical fields. They are being investigated for treating heart disease, a leading cause of death worldwide, in neurological disorders, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Stem cell therapies, for example, have shown promise in repairing damaged heart tissue and improving heart function in patients with heart failure. For instance, CRISPR/Cas9 is a gene-editing technology that enables regenerative medicine 2.0 by directing cell fate. The CRISPR/Cas9 system exploits the concerted action of Cas9 nuclease and programmable single guide RNA (sgRNA) and has been widely used for genome editing. Researchers are using CRISPR/Cas9 to protect transplanted cells from the patient's immune system by ex vivo editing. CRISPR/Cas9-based gene therapy has been used to correct hereditary tyrosinemia, a rare metabolic disorder. Researchers at the University of Massachusetts, the Massachusetts Institute of Technology (MIT), and Oregon Health Sciences University (OHSU) succeeded recently in CRISPR-Cas9-based gene therapy.

Additionally, the field of regenerative medicine is rapidly growing, with many different segments and subfields experiencing significant progress and innovation. The driving force behind the development of regenerative medicines includes the increasing prevalence of chronic diseases, the aging population, and the limitations of current treatments for tissue damage and degenerative conditions. Regenerative medicines have the potential to offer more effective and long-lasting solutions for these conditions. The technology used to develop and manufacture regenerative medicnes includes biotechnology, cell culture, gene editing, and nanotechnology. These technologies enable the precise manipulation of cells and genetic material to create customized regenerative therapies.

Scientific and technological advancements in the healthcare sector

The growing need for regenerative medicines in the healthcare sector is mainly due to scientific advancements. Recent advancements in stem cell research have led to the development of new therapies for a wide range of diseases, including heart disease, Parkinson's disease, and diabetes. This is in turn driving the growth of regenerative medicines. For instance, in 2020, Novartis received approval from the European Medicines Agency for its gene therapy Zolgensma, which is used to treat spinal muscular atrophy. Zolgensma is the world's most expensive medicine, with a list price of $2.1 million per dose.

Moreover, tissue engineering involves the use of biomaterials, cells, and other components to create artificial tissues and organs. Advances in tissue engineering techniques, such as 3D printing and biomaterials development, have led to the creation of functional tissues and organs, such as heart tissue, liver tissue, and skin. For instance, BlueRock Therapeutics, a company focused on developing cell-based therapies for neurological disorders, announced positive preclinical data for its Parkinson's disease program in 2020. The data demonstrated that BlueRock's cell-based therapy improved motor function in animal models of Parkinson's disease.

Additionally, research of disease mechanisms at the molecular and cellular levels has led to the identification of new therapeutic targets and the development of more targeted therapies. This understanding has also led to the identification of biomarkers that can be used to diagnose diseases and monitor treatment effectiveness. Gene editing technologies, such as CRISPR-Cas9, allow researchers to precisely edit and modify genes, which have significant potential for the development of new therapies. For example, gene editing can be used to correct genetic mutations that cause inherited diseases or to enhance the immune system to fight cancer.

Furthermore, government support and funding for regenerative medicine research and development is also a key driver of the regenerative medicine market. Governments around the world are investing in regenerative medicine research and providing funding for clinical trials, which is helping to advance the field and bring new therapies to market. For instance, ana Biotechnology, a company focused on developing cell-based therapies, raised US$700 million in funding in 2020. The funding will be used to advance Sana's pipeline of cell-based therapies, including treatments for cancer and genetic diseases.

The global regenerative medicine market for stem cell therapy technology

Stem cell therapy is a rapidly growing field of regenerative medicine that involves using stem cells to repair or replace damaged tissues and organs. Stem cells are undifferentiated cells that can differentiate into different cell types in the body, which makes them ideal for treating a wide range of diseases and conditions.

The prevalence of chronic diseases such as diabetes, heart disease, and cancer are increasing worldwide, leading to a higher demand for innovative and effective treatments. Stem cell therapy offers a promising solution to treat these conditions by repairing or replacing damaged tissues and organs. The World Health Organization (WHO) estimates that there were 19.3 million new cancer cases and 10 million cancer-related deaths worldwide in 2020. This highlights the significant global burden of cancer and the need for effective treatments such as stem cell therapy. Additionally, the field of stem cell therapy has received significant investment and funding in recent years, which has led to increased research and development of new therapies. The National Institutes of Health (NIH) in the United States is one of the largest government funders of stem cell research. In 2019, the NIH invested over $1.5 billion in stem cell research, demonstrating the significant level of government support for this technology.

Moreover, advances in stem cell technology, such as induced pluripotent stem cells (iPSCs) and CRISPR gene editing, have made it easier to generate and manipulate stem cells, leading to more efficient and effective therapies.

Impact of severe ailments on the market

Furthermore, the prevalence of severe ailments like cancer, dementia, Parkinson's, and Alzheimer's disease also has a significant impact on the stem cell therapy segment. Stem cell therapy has the potential to be used in the treatment of various types of cancer, including blood cancers such as leukemia and lymphoma, as well as solid tumors such as breast and lung cancer. The number of cancer cases can drive demand for stem cell therapies as a potential treatment option. For example, in the case of blood cancers, stem cell transplantation is a well-established therapy that can be used to replace diseased or damaged bone marrow with healthy stem cells. As the number of cancer cases increases, the demand for stem cell transplantation is also likely to increase. In addition to being used as a treatment option, stem cell therapy is also a promising area of research for developing new cancer treatments. For example, stem cells can be genetically modified to produce anti-cancer agents or to target cancer cells specifically. This approach has shown promise in preclinical studies and is being explored in clinical trials. As such, the number of cancer cases can have an impact on the stem cell therapy segment of the regenerative medicine market by driving demand for new treatments, increasing investment in research and development, and influencing the availability of funding and resources.

USA in North America is predicted to hold the largest market share for the market

Regenerative medicine enables healthy cells and tissue generation which can replace cells that are damaged due to some major diseases or injuries. Such medicines, due to their high regenerative potential, are finding their way into gene therapies and tissue engineering.

Growing prevalence of cardiovascular and skin diseases coupled with the surge in accidental injuries has provided a positive outlook to regenerative medicines in the United States since such medicines would be used for wound healing in injuries and for replacing irreversibly damaged heart and skin tissue. According to the data provided by the Centers for Disease Control and Prevention, the number of deaths that occurred due to heat attacks in the United States stood at 6,97,000 which signified a 5.7% increase in deaths in comparison to 2019's death figure. Also, as per the same source, the number of Americans who died due to coronary heart disease stood at 3,82,820.

Skin diseases are also one of the major diseases affecting Americans. According to the American Academy of Dermatology Association, 50 million Americans get affected by skin conditions such as atopic dermatitis, psoriasis, rosacea, and skin cancer on annual basis.

The growing emphasis on regenerative medicine development in the United States market has made various companies to establish their manufacturing facilities in the country. for instance, in April 2022, Enzyvant announced its plan to establish its manufacturing facility in North Carolina. the 25,972 square-foot facility will be focused on developing regenerative medicines for rare diseases such as congenital athymia. besides facilities establishments, the comprehensive regenerative medicine policy announced by the Food and Drug Administration (FDA) in November 2017, has also established a framework for the development of such medicine in the United States, thereby augmenting the overall market growth during the forecast period.

Market Key Developments

  • In September 2022, Alkem Laboratories partnered with Stempeutics to introduce the first cell therapy medicine made in India, named "StemOne," which is designed to treat Knee Osteoarthritis. The product has been granted regulatory approval by the Drugs Controller General of India (DCGI), marking the first commercial use of an allogeneic cell therapy product in India for treating Knee OA. StemOne is composed of cultured-pooled, allogeneic mesenchymal stromal cells that are derived from bone marrow.

Segmentation:

By Technology

  • Stem cell Therapy
  • Gene Therapy
  • Tissue Engineering
  • Others

By Application

  • Cardiovascular
  • Oncology
  • Dermatology
  • Orthopedics and Musculoskeletal
  • Wound Healing
  • Ophthalmology
  • Others

By End-User

  • Hospitals
  • Clinics
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Data
  • 2.3. Validation

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. GLOBAL REGENERATIVE MEDICINE MARKET BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Stem cell Therapy
  • 5.3. Gene Therapy
  • 5.4. Tissue Engineering
  • 5.5. Others

6. GLOBAL REGENERATIVE MEDICINE MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Cardiovascular
  • 6.3. Oncology
  • 6.4. Dermatology
  • 6.5. Orthopedics and Musculoskeletal
  • 6.6. Wound Healing
  • 6.7. Ophthalmology
  • 6.8. Others

7. GLOBAL REGENERATIVE MEDICINE MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Clinics
  • 7.4. Others

8. GLOBAL REGENERATIVE MEDICINE MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
    • 8.2.4.1. USA
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Technology
    • 8.3.2. By Application
    • 8.3.3. By End-User
    • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Technology
    • 8.4.2. By Application
    • 8.4.3. By End-User
    • 8.4.4. By Country
    • 8.4.4.1. Germany
    • 8.4.4.2. UK
    • 8.4.4.3. Spain
    • 8.4.4.4. France
    • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Technology
    • 8.5.2. By Application
    • 8.5.3. By End-User
    • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. UAE
    • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Technology
    • 8.6.2. By Application
    • 8.6.3. By End-User
    • 8.6.4. By Country
    • 8.6.4.1. China
    • 8.6.4.2. Japan
    • 8.6.4.3. India
    • 8.6.4.4. South Korea
    • 8.6.4.5. Indonesia
    • 8.6.4.6. Thailand
    • 8.6.4.7. Taiwan
    • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisition, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. Novartis
  • 10.2. Biogen
  • 10.3. GlaxoSmithKline (GSK)
  • 10.4. Baxter International, Inc.
  • 10.5. Boehringer Ingelheim
  • 10.6. Amgen Inc.
  • 10.7. Integra Lifesciences Corp.